Could a vaccine made from your own cancer cells beat melanoma?

NCT ID NCT01753089

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage trial tested a custom-made vaccine called WDVAX in 23 people with advanced melanoma. The vaccine is created from each patient's own killed tumor cells, mixed with immune-boosting proteins, and formed into a small dissolvable tablet. The goal was to see if it's safe and possible to make, and whether it can train the immune system to fight the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
WDVAX (a vaccine made from the patient's own killed melanoma cells combined with immune-boosting proteins GM-CSF and CpG, formed into a dissolvable scaffold)
What this could lead to
If it works, this could point toward a personalized vaccine that trains the immune system to attack melanoma.
What could go wrong
This is a very early Phase I trial with only 23 people, focused on safety and feasibility. The vaccine may not trigger a strong enough immune response or shrink tumors, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Brigham and Women's Hospital

    Boston, Massachusetts, 02215, United States

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.